LifeVantage Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Los beneficios de LifeVantage han disminuido a una tasa media anual de -10.6%, mientras que en la industria Personal Products los beneficios crecieron en un 1.9% anualmente. Los ingresos han ido disminuyendo a una tasa media de 0.3% al año. La rentabilidad financiera de LifeVantage es de 23.8%, y sus márgenes netos son de 3.7%.
Información clave
-10.60%
Tasa de crecimiento de los beneficios
-5.93%
Tasa de crecimiento del BPA
| Crecimiento de la industria Personal Products | 20.87% |
| Tasa de crecimiento de los ingresos | -0.35% |
| Rentabilidad financiera | 23.83% |
| Margen neto | 3.74% |
| Próxima actualización de resultados | 06 May 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential
Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential
Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding
Feb 06
LFVN: Gut Health Research Progress Will Support Confident Upside Potential
Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential
Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).LFVN: Gut Study Progress Will Drive Future Upside Potential
Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).LFVN: Future Gut Health Research And Buybacks Will Drive Upside
Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.LFVN: Future Index Inclusion Will Drive Upside Potential
Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).LFVN: Share Repurchases and New Index Addition Will Drive Value
LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop
Nov 14We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease
Nov 04It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks
Sep 30LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045
Sep 05The LifeVantage Advantage: High Retention, High Returns
Jul 21Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality
May 13What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
May 02
New Initiatives Will Drive MindBody GLP-1 System's Future Success
Expansion into international markets and enhanced supply chain capacity are expected to drive significant revenue growth and stabilize future sales.LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.04
Feb 09LifeVantage Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 07LifeVantage: Post-Earnings Sell-Off Provides Buying Opportunity
Feb 06LifeVantage Corporation (NASDAQ:LFVN) Looks Just Right With A 33% Price Jump
Feb 05What Is LifeVantage Corporation's (NASDAQ:LFVN) Share Price Doing?
Feb 01Market Participants Recognise LifeVantage Corporation's (NASDAQ:LFVN) Earnings Pushing Shares 31% Higher
Dec 20LifeVantage (NASDAQ:LFVN) Will Be Hoping To Turn Its Returns On Capital Around
Dec 16LifeVantage's (NASDAQ:LFVN) Dividend Will Be $0.04
Nov 16LifeVantage's (NASDAQ:LFVN) Dividend Will Be $0.04
Nov 02Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero LifeVantage. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 25 | 210 | 8 | 157 | 0 |
| 30 Sep 25 | 229 | 10 | 172 | 0 |
| 30 Jun 25 | 229 | 10 | 171 | 0 |
| 31 Mar 25 | 222 | 9 | 166 | 0 |
| 31 Dec 24 | 212 | 7 | 158 | 0 |
| 30 Sep 24 | 196 | 4 | 149 | 0 |
| 30 Jun 24 | 200 | 3 | 154 | 0 |
| 31 Mar 24 | 205 | 4 | 159 | 0 |
| 31 Dec 23 | 211 | 3 | 164 | 0 |
| 30 Sep 23 | 213 | 3 | 166 | 0 |
| 30 Jun 23 | 213 | 3 | 166 | 0 |
| 31 Mar 23 | 210 | -1 | 165 | 0 |
| 31 Dec 22 | 206 | -1 | 163 | 0 |
| 30 Sep 22 | 205 | 0 | 162 | 0 |
| 30 Jun 22 | 206 | 3 | 161 | 0 |
| 31 Mar 22 | 210 | 9 | 160 | 0 |
| 31 Dec 21 | 212 | 10 | 162 | 0 |
| 30 Sep 21 | 219 | 14 | 162 | 0 |
| 30 Jun 21 | 220 | 13 | 164 | 0 |
| 31 Mar 21 | 225 | 12 | 169 | 0 |
| 31 Dec 20 | 229 | 12 | 172 | 0 |
| 30 Sep 20 | 232 | 12 | 177 | 0 |
| 30 Jun 20 | 233 | 12 | 179 | 0 |
| 31 Mar 20 | 230 | 12 | 177 | 0 |
| 31 Dec 19 | 230 | 12 | 177 | 0 |
| 30 Sep 19 | 227 | 8 | 178 | 0 |
| 30 Jun 19 | 226 | 7 | 178 | 0 |
| 31 Mar 19 | 224 | 7 | 179 | 0 |
| 31 Dec 18 | 218 | 6 | 174 | 0 |
| 30 Sep 18 | 210 | 6 | 164 | 0 |
| 30 Jun 18 | 203 | 6 | 158 | 0 |
| 31 Mar 18 | 200 | 3 | 157 | 0 |
| 31 Dec 17 | 194 | 1 | 154 | 0 |
| 30 Sep 17 | 194 | 1 | 156 | 0 |
| 30 Jun 17 | 199 | 2 | 162 | 0 |
| 31 Mar 17 | 202 | 4 | 161 | 0 |
| 31 Dec 16 | 213 | 5 | 167 | 0 |
| 30 Sep 16 | 216 | 6 | 168 | 0 |
| 30 Jun 16 | 207 | 6 | 159 | 0 |
| 31 Mar 16 | 199 | 4 | 156 | 0 |
| 31 Dec 15 | 188 | 3 | 149 | 0 |
| 30 Sep 15 | 184 | 3 | 146 | 0 |
| 30 Jun 15 | 190 | 7 | 148 | 0 |
Ingresos de calidad: LFVN tiene un alto nivel de ganancias no monetarias.
Margen de beneficios creciente: Los actuales márgenes de beneficio (3.7%) de LFVN son superiores a los del año pasado (3.5%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de LFVN han disminuido en un 10.6% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de LFVN en el último año (7.1%) supera su media de 5 años (-10.6% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de LFVN en el último año (7.1%) superó al de la industria Personal Products 2.5%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (23.8%) de LFVN se considera alta.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/05 21:20 |
| Precio de las acciones al final del día | 2026/05/05 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
LifeVantage Corporation está cubierta por 5 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Mitchell Pinheiro | Imperial Capital |
| Ryan Meyers | Lake Street Capital Markets, LLC |